Joanne Quan Sells 6,911 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insider Joanne Quan sold 6,911 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $90.27, for a total value of $623,855.97. Following the completion of the transaction, the insider owned 11,305 shares in the company, valued at $1,020,502.35. This represents a 37.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Mirum Pharmaceuticals Price Performance

NASDAQ:MIRM opened at $96.03 on Friday. Mirum Pharmaceuticals, Inc. has a 52 week low of $36.88 and a 52 week high of $96.13. The stock’s fifty day moving average is $76.87 and its two-hundred day moving average is $70.34. The company has a market capitalization of $4.93 billion, a P/E ratio of -111.66 and a beta of 0.48. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15. The firm had revenue of $133.01 million during the quarter, compared to the consensus estimate of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company’s quarterly revenue was up 47.1% on a year-over-year basis. During the same period last year, the company earned ($0.30) EPS. Equities analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Comerica Bank increased its holdings in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares during the period. AQR Capital Management LLC grew its position in shares of Mirum Pharmaceuticals by 307.3% during the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock worth $2,211,000 after buying an additional 37,028 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Mirum Pharmaceuticals by 7.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock worth $1,176,000 after buying an additional 1,720 shares during the period. Caxton Associates LLP purchased a new stake in shares of Mirum Pharmaceuticals during the first quarter worth approximately $217,000. Finally, Empowered Funds LLC raised its holdings in Mirum Pharmaceuticals by 15.4% in the first quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock valued at $1,729,000 after acquiring an additional 5,120 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Wall Street Zen raised shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 17th. Raymond James Financial restated a “strong-buy” rating and set a $110.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. Stifel Nicolaus lifted their price objective on Mirum Pharmaceuticals from $92.00 to $98.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Cantor Fitzgerald reissued an “overweight” rating and set a $130.00 target price on shares of Mirum Pharmaceuticals in a research note on Monday, December 8th. Finally, TD Cowen restated a “buy” rating on shares of Mirum Pharmaceuticals in a report on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Mirum Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $102.58.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.